Dotterud et al. [30] reported a reduction in the overall incidence of AD at two years, and this effect was greatest in the non-IgE-associated AD subgroup, as there was no effect in the IgE-associated subgroup. The gene discussed is IGHE; the disease is Alzheimer disease.